Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.
MicroMedic's CellDetect assay detects early-stage urothelial bladder cancer in about 20 minutes using a unique plant-based dye.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.
The firm is also developing a second system designed to run clinical chemistry tests for low- and medium-volume labs.
Since introducing new clinical platforms last year, Sciex has launched an automated sample prep system while Thermo Fisher has begun customer beta testing.
The company was encouraged by the clinical use of the existing handheld instrument in hospitals and soon plans to launch it with a broader menu, it said at AACC.
A spin-out of the University of Geneva and Barcelona's Vall d’Hebron Research Institute, the company is focused on protein biomarkers for brain injury.